

BIOCRYST PHARMACEUTICALS INC  
Form 8-K  
November 10, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 18, 2008**

**BioCryst Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other Jurisdiction of  
Incorporation)

**000-23186**

(Commission File Number)

**62-1413174**

(IRS Employer Identification No.)

**2190 Parkway Lake Drive, Birmingham, Alabama**

(Address of Principal Executive Offices)

**35244**

(Zip Code)

Registrant's telephone number, including area code: **(205) 444-4600**

**NOT APPLICABLE**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 9.01. Financial Statements and Exhibits.**

The following document extends the period of the SWO until November 17, 2008. It is being filed with this Form 8-K solely because it was inadvertently omitted from our Form 10-Q filed on October 31, 2008. The total contract amount remains unchanged (\$102,661,429). The contract completion date remains unchanged (December 31, 2010).

**Exhibit**

**Number**

**Description**

|      |   |
|------|---|
| 10.1 | Amendment of Solicitation/Modification of Contract. |
|------|---|

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioCryst Pharmaceuticals, Inc.**

Date: November 7, 2008

By: /s/ Michael A. Darwin

Name: Michael A. Darwin

Title: Vice President Finance

**EXHIBIT INDEX**

| <b>Exhibit<br/>Number</b> | <b>Description</b>                                  |
|---------------------------|---|
| 10.1                      | Amendment of Solicitation/Modification of Contract. |